CA2397256A1 - Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives - Google Patents

Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives Download PDF

Info

Publication number
CA2397256A1
CA2397256A1 CA002397256A CA2397256A CA2397256A1 CA 2397256 A1 CA2397256 A1 CA 2397256A1 CA 002397256 A CA002397256 A CA 002397256A CA 2397256 A CA2397256 A CA 2397256A CA 2397256 A1 CA2397256 A1 CA 2397256A1
Authority
CA
Canada
Prior art keywords
6alkyl
hydrogen
6alkyloxy
formula
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002397256A
Other languages
English (en)
French (fr)
Inventor
Mary Ellen Margaret Rybak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2397256A1 publication Critical patent/CA2397256A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002397256A 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives Abandoned CA2397256A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00200695 2000-02-29
EP00200695.5 2000-02-29
PCT/EP2001/002167 WO2001064198A2 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives

Publications (1)

Publication Number Publication Date
CA2397256A1 true CA2397256A1 (en) 2001-09-07

Family

ID=8171114

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002397256A Abandoned CA2397256A1 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives

Country Status (5)

Country Link
EP (1) EP1267871A2 (de)
JP (1) JP2003525238A (de)
AU (1) AU2001239275A1 (de)
CA (1) CA2397256A1 (de)
WO (1) WO2001064198A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1792927B1 (de) 2004-09-22 2013-03-06 Nippon Kayaku Kabushiki Kaisha Neues blockcopolymer, micellenzubereitung und antikrebsmittel, das diese als wirkbestandteil enthält
EP2545919A1 (de) 2005-12-23 2013-01-16 Link Medicine Corporation Behandlung von Synucleinopathien
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
AU2007252678A1 (en) 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of podophyllotoxin
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
JP5548365B2 (ja) 2006-11-08 2014-07-16 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
EP2206502B1 (de) 2007-09-28 2018-09-12 Nippon Kayaku Kabushiki Kaisha Polymer-konjugat eines steroids
CN101977631A (zh) 2008-03-18 2011-02-16 日本化药株式会社 生理活性物质的高分子量偶联物
JP5366940B2 (ja) 2008-05-08 2013-12-11 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
EP2431403B1 (de) 2009-05-15 2016-09-28 Nipponkayaku Kabushikikaisha Polymerkonjugat aus einer bioaktiven substanz mit einer hydroxidgruppe
TW201304805A (zh) 2010-11-17 2013-02-01 Nippon Kayaku Kk 新穎之胞核苷系代謝拮抗劑之高分子衍生物
PT2754682T (pt) 2011-09-11 2017-08-29 Nippon Kayaku Kk Método para o fabrico de copolímero de bloco
BR112015008308A2 (pt) 2012-10-16 2017-12-05 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por metileno do ror-gama-t
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
SG11201502935VA (en) 2012-10-16 2015-09-29 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CA2288140C (en) * 1997-04-25 2007-04-03 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
PE20000042A1 (es) * 1997-12-22 2000-02-17 Schering Corp Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas
WO1999065494A1 (en) * 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000001382A1 (en) * 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
UA71592C2 (uk) * 1998-12-23 2004-12-15 Янссен Фармацевтика Н.В. Похідні 1,2-анельованого хіноліну, спосіб їх одержання (варіанти), фармацевтична композиція, що їх містить, проміжна сполука та спосіб її одержання

Also Published As

Publication number Publication date
JP2003525238A (ja) 2003-08-26
AU2001239275A1 (en) 2001-09-12
WO2001064198A3 (en) 2002-03-21
EP1267871A2 (de) 2003-01-02
WO2001064198A2 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
CA2397349A1 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
CA2397256A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
CA2397657A1 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
CA2397240A1 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
CA2396865C (en) Farnesyl protein transferase inhibitors for treating breast cancer
CA2397446A1 (en) Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
CA2397558A1 (en) Dosing regimen
CA2397694A1 (en) Farnesyl protein transferase inhibitor combinations
CA2397690A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
CA2397425A1 (en) Farnesyl protein transferase inhibitor combinations with taxane compounds
CA2397448A1 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
CA2397253A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
US20030050323A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
US20030060480A1 (en) Farnesyl protein transferase inhibitor combinations with vinca alkaloids
CA2397475A1 (en) Farnesyl protein transferase inhibitor combinations with vinca alkaloids
US20030125268A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives

Legal Events

Date Code Title Description
FZDE Dead